| Adrian E Varela, MD | |
|
10330 Se 32nd Ave, Suite 320, Milwaukie, OR 97222-6587 | |
| (503) 513-2200 | |
| Not Available |
| Full Name | Adrian E Varela |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 25 Years |
| Location | 10330 Se 32nd Ave, Milwaukie, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366452054 | NPI | - | NPPES |
| 027740 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD25584 (Oregon) | Primary |
| 207YS0012X | Otolaryngology - Sleep Medicine | MD25584 (Oregon) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Milwaukie Hospital | Milwaukie, OR | Hospital |
| Legacy Emanuel Medical Center | Portland, OR | Hospital |
| Legacy Good Samaritan Medical Center | Portland, OR | Hospital |
| Providence Portland Medical Center | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Ent And Allergy Care Inc | 3870692718 | 4 |
News Archive
The vegetables most boys wanted to avoid in childhood - such as kale and broccoli - just may be the answer to staving off prostate cancer growth in adulthood. A new clinical trial at UC San Diego Moores Cancer Center will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer.
BioSante Pharmaceuticals, Inc., announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.
Australian researchers have found that cells containing cancer could soon be detected using a simple test. The test could one day change how cancers are diagnosed, the team says. The results of the study to develop the test were published in the journal Nature Communications.
Bristol-Myers Squibb Company today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.
› Verified 3 days ago
| Entity Name | Northwest Ent And Allergy Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700927928 PECOS PAC ID: 3870692718 Enrollment ID: O20070619000229 |
News Archive
The vegetables most boys wanted to avoid in childhood - such as kale and broccoli - just may be the answer to staving off prostate cancer growth in adulthood. A new clinical trial at UC San Diego Moores Cancer Center will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer.
BioSante Pharmaceuticals, Inc., announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.
Australian researchers have found that cells containing cancer could soon be detected using a simple test. The test could one day change how cancers are diagnosed, the team says. The results of the study to develop the test were published in the journal Nature Communications.
Bristol-Myers Squibb Company today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adrian E Varela, MD 10330 Se 32nd Avenue, Suite 320, Milwaukie, OR 97222 Ph: (503) 513-8693 | Adrian E Varela, MD 10330 Se 32nd Ave, Suite 320, Milwaukie, OR 97222-6587 Ph: (503) 513-2200 |
News Archive
The vegetables most boys wanted to avoid in childhood - such as kale and broccoli - just may be the answer to staving off prostate cancer growth in adulthood. A new clinical trial at UC San Diego Moores Cancer Center will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer.
BioSante Pharmaceuticals, Inc., announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.
Australian researchers have found that cells containing cancer could soon be detected using a simple test. The test could one day change how cancers are diagnosed, the team says. The results of the study to develop the test were published in the journal Nature Communications.
Bristol-Myers Squibb Company today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.
› Verified 3 days ago